Get started
NOVO NORDISK A/SNOVO NORDISK A/SNOVO NORDISK A/S

NOVO NORDISK A/S

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NOV chart


Full chart

Key facts today


Novo Nordisk will skip early development and start late-stage trials for its obesity drug, amycretin, in early 2026. Analysts note promising results, with a 22% weight loss at the highest dose.
Novo Nordisk signed an $812 million licensing deal with U.S. biotech Deep Apple for a weight-loss drug and announced a partnership with Septerna to develop oral small-molecule weight-loss drugs.
Novo Nordisk A/S released its Quarterly Trading Report for Q1 2025, providing insights into the company's financial performance and market activities during the first quarter of the year.
Analyze the impactAnalyze the impact

NOV upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪289.57 B‬ CHF
Dividend yield (indicated)
2.20%
Price to earnings Ratio (TTM)
22.239
Basic EPS (TTM)
3.013 CHF
Net income (FY)
‪12.69 B‬ CHF
Revenue (FY)
‪36.50 B‬ CHF
Shares float
‪3.16 B‬
Beta (1Y)
1.42

Employees


Employees (FY)
‪76.3 K‬
Change (1Y)
‪+12.93 K‬ +20.41%
Revenue / Employee (1Y)
‪478.39 K‬ CHF
Net income / Employee (1Y)
‪166.36 K‬ CHF

About NOVO NORDISK B A/S


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Lars Fruergaard Jørgensen
Website
novonordisk.com
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG006M6YKB4
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NOV news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NOV highest yielding bonds


N
XS300255582
NOVO NO.F.NL 25/37 MTN
Yield to maturity
3.62%
Maturity date
May 27, 2037
N
XS282046075
NOVO NO.F.NL 24/34 MTN
Yield to maturity
3.32%
Maturity date
May 21, 2034
N
XS300255353
NOVO NO.F.NL 25/33 MTN
Yield to maturity
3.15%
Maturity date
May 27, 2033
N
XS282045567
NOVO NO.F.NL 24/31 MTN
Yield to maturity
2.90%
Maturity date
Jan 21, 2031
N
XS300255329
NOVO NO.F.NL 25/30 MTN
Yield to maturity
2.87%
Maturity date
Aug 27, 2030
XS244124704
NOVO NO.F.NL 22/30MTN
Yield to maturity
2.84%
Maturity date
Mar 31, 2030
N
XS282045460
NOVO NO.F.NL 24/29 MTN
Yield to maturity
2.59%
Maturity date
Jan 21, 2029
XS234803042
NOVO NO.F.NL 21/28
Yield to maturity
2.57%
Maturity date
Jun 4, 2028
N
XS300255299
NOVO NO.F.NL 25/28 MTN
Yield to maturity
2.56%
Maturity date
May 27, 2028
N
XS300255213
NOVO NO.F.NL 25/27 FLRMTN
Yield to maturity
2.50%
Maturity date
May 27, 2027
XS244933017
NOVO NO.F.NL 22/27MTN
Yield to maturity
2.41%
Maturity date
Sep 30, 2027

See all NOV bonds 

Sparks


Curated watchlists where NOV is featured.

See all sparks 


Check out other big names from the same industry as NOV.

Frequently Asked Questions


The current price of NOV is 65.027 CHF — it has decreased by −0.72% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange NOVO NORDISK A/S stocks are traded under the ticker NOV.
NOV stock has risen by 7.05% compared to the previous week, the month change is a 17.87% rise, over the last year NOVO NORDISK A/S has showed a −49.43% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOV price has a max estimate of 112.71 CHF and a min estimate of 43.83 CHF. Watch NOV chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOV reached its all-time high on Jun 25, 2024 with the price of 132.543 CHF, and its all-time low was 38.231 CHF and was reached on Jun 29, 2021. View more price dynamics on NOV chart.
See other stocks reaching their highest and lowest prices.
NOV stock is 3.04% volatile and has beta coefficient of 1.42. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of ‪288.02 B‬, it has increased by 1.58% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.84 CHF per share, whereas the estimation was 0.78 CHF resulting in a 6.95% surprise. The estimated earnings for the next quarter are 0.75 CHF per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to ‪10.02 B‬ CHF, despite the estimated figure of ‪10.00 B‬ CHF. In the next quarter, revenue is expected to reach ‪9.77 B‬ CHF.
NOV net income for the last quarter is ‪3.72 B‬ CHF, while the quarter before that showed ‪3.55 B‬ CHF of net income which accounts for 4.95% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 14, 2025, the company has ‪76.3 K‬ employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is ‪20.12 B‬ CHF, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.